Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Paré, Guillermo Villacampa, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso‐Sousa, Patricia Villagrasa, Michelle K. DeMeo, Molly DiLullo, Jorge Gómez Tejeda Zañudo, Jakob Weiß, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer
Topics & Concepts
TrastuzumabMedicineBreast cancerInternal medicineClinical endpointPaclitaxelOncologyAdjuvantCancerClinical trialHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesBreast Lesions and Carcinomas